Haematologica (Jan 2008)

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

  • A. Kalff,
  • J. Shortt,
  • J. Farr,
  • R. McLennan,
  • A. Lui,
  • J. Scott,
  • A. Spencer

DOI
https://doi.org/10.3324/haematol.11933
Journal volume & issue
Vol. 93, no. 1

Abstract

Read online

LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.